Oricell Therapeutics raised more than $110 million in a pre-IPO round to expand its solid-tumor CAR-T program, betting that armored autologous approaches can overcome the immune suppression common in solid cancers. The money is intended to advance Ori-C101, a GPC3-targeted autologous CAR T for advanced hepatocellular carcinoma toward registrational trials. The company described the financing as oversubscribed and co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and another global healthcare fund. OriCAR-017 is also in early clinical testing in China for multiple myeloma, with additional pipeline candidates in development. The round highlights continued capital access for platform-style oncology cell therapies as companies look to close the gap between early signals and late-stage registrational execution.